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Proteasome is responsible for cellular
protein proteolysis, but the turnover of
the proteasome subunit itself is still
unknown. Li et al. show that the ubiquitin-
proteasomal degradation of PSMA7
subunit and cellular proteasome
abundance is regulated by c-Abl kinase.
c-Abl plays dual roles in the regulation of
proteasome homeostasis and activities.
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The ubiquitin-proteasome system is a vital proteo-
lytic pathway required for cell homeostasis. However,
the turnover mechanism of the proteasome subunit
itself is still not understood. Here, we show that the
20S proteasome subunit PSMA7 is subjected to ubiq-
uitination and proteasomal degradation, which was
suppressed by PSMA7 phosphorylation at Y106
mediated by the nonreceptor tyrosine kinases c-
Abl/Arg. BRCA1 specifically functions as an E3 ubiq-
uitin ligase of PSMA7 ubiquitination. c-Abl/Arg regu-
lates cellular proteasome abundance by controlling
the PSMA7 subunit supply. Downregulated PSMA7
level results in decreased proteasome abundance
in c-Abl/Arg RNAi-knockdown or c-abl/arg-deficient
cells, which demonstrated an increased sensitivity
to proteasome inhibition. In response to oxidative
stress, the c-Abl-mediated upregulation of protea-
some level compensates for the proteasomal activity
impairment induced by reactive oxygen species. Abl-
kinases-regulated biogenesis and homeostasis of
proteasome complexes may be important for under-
standing related diseases and pathological states.INTRODUCTION
ATP-dependent ubiquitin-proteasomal proteolysis is respon-
sible for rapid and irreversible protein turnover in the cell (Finley,
2009; Pickart and Cohen, 2004). In mammals, the evolutionarily
conserved proteasome contains at least 33 different protein
subunits (Bedford et al., 2010; Murata et al., 2009). The 20S
core particle (CP) of the proteasome is arranged into four-
stacked hetero-oligomeric rings (abba) composed of seven a
subunits (a1–a7) and seven b subunits (b1–b7), three of which
(b1, b2, and b5) are proteolytically active subunits (Groll et al.,
1997). The 20S CP is usually capped at one or both ends by484 Cell Reports 10, 484–496, February 3, 2015 ª2015 The Authorsthe 19S regulatory particle to form a complete 26S/30S protea-
some (Leggett et al., 2002; Navon and Goldberg, 2001).
The biogenesis of the proteasome is a highly orchestrated,
multistep event involving the biosynthesis, assembly, and matu-
ration of each of the subunits. Coordinated transcription of
proteasome subunit (PSM) genes is regulated by nuclear-fac-
tor-erythroid-derived 2-related factor 1 (Nrf1) and Nrf2 in mam-
mals (Pickering et al., 2012; Radhakrishnan et al., 2010) and by
the short-lived transcription factor Rpn4 in yeast (Xie and Var-
shavsky, 2001). The maturation of mammalian 20S proteasome
is significantly dependent on proteasome assembling chaper-
ones and proteassemblin POMP (Le Tallec et al., 2007; Murata
et al., 2009). Proteasome abundance is also highly regulated
by proteasome turnover, which contributes to a rapid switch
between constitutive proteasome and immunoproteasome in
response to interferon-g (Heink et al., 2005). However, to our
knowledge, the mechanism by which the turnover of constitutive
20S CP subunits is regulated is still unknown.
The nonreceptor tyrosine kinases c-Abl (Abl1) and Arg (abl-
related gene; Abl2) are ubiquitously expressed in mammalian
tissues and share 90% homology at N-terminal SH3, SH2,
and kinase domain, implying their overlapping functions related
to cell proliferation, survival, adhesion, migration, and cellular
stress responses (Pendergast, 2002). c-Abl is activated by stim-
uli such as growth factors, reactive oxygen species (ROS), and
DNA damages (Plattner et al., 1999; Sun et al., 2000). Mice
with disruption of c-Abl or Arg are viable, whereas embryos defi-
cient in both c-abl and arg exhibit defects in neurulation and die
prior to 11 days postcoitus, which suggests that c-Abl/Arg may
play pivotal functions in developmental processes (Koleske
et al., 1998). Notably, as a result of chromosomal translocation,
the constitutively active Bcr-Abl chimeric proteins that present in
95% of patients with chronic myeloid leukemia (CML) were
shown to be involved in CML by inducing abnormal cell prolifer-
ation, adhesion, migration, and DNA repair pathways.
The PSMA7 (a4) subunit is one of the constitutive a subunits of
mammalian 20S proteasome and an association target of spe-
cific proteasome-regulation proteins (Cho et al., 2001; Da¨chsel
et al., 2005). Our previous work has shown that the c-Abl and
Arg tyrosine kinases directly interact with and phosphorylate
Figure 1. c-Abl Kinase Phosphorylates PSMA7 at Y106
(A) Anti-PSMA7 immunoprecipitates prepared from the whole lysates of wild-type or c-abl/arg/MEFs were normalized by PSMA7 level and then analyzed by
immunoblotting. IgG immunoprecipitates were used as a control. IB, immunoblot; IP, immunoprecipitation; WT, wild-type.
(B and C) PSMA7-FLAG coexpressed with Myc-c-Abl in the whole (B) or fractionated proteasome-containing fraction (C) of HEK293 cells extracts were purified
by anti-FLAG immunoprecipitation and then subjected to trypsinization and LC-MS/MS analysis. The monophosphorylated peptides 96LTVEDPVTVEY(P)ITR109
containing PO3
-modified Y106 were identified.
(D) Anti-FLAG immunoprecipitates prepared from the fractionated lysates of HEK293 cells coexpressing Myc-c-Abl and the indicated proteins were normalized
by PSMA7-FLAG level and then detected by immunoblotting.the PSMA7 subunit both in vitro and in vivo and that protea-
somes loaded with tyrosine-phosphorylated PSMA7 have
decreased proteolytic activity (Liu et al., 2006). In this study,
we expanded on this work to show that Abl-kinases-mediated
PSMA7 phosphorylation significantly suppressed the ubiquitin-
proteasomal degradation of PSMA7 and therefore contributed
to the regulation of cellular proteasome abundance.
RESULTS
c-Abl Kinase Phosphorylates PSMA7 at Y106
In concert with our previous findings, PSMA7was tyrosine phos-
phorylated by Abl kinase in wild-type, but not in c-abl/arg-defi-
cient, mouse embryonic fibroblasts (MEFs) (Figure 1A). To
further analyze the potential phosphorylation site, the FLAG-
tagged PSMA7 ectopically coexpressed with c-Abl in HEK293
cells was subjected to mass spectrometry analysis (liquid chro-
matography-tandem mass spectrometry [LC-MS/MS]). The re-
sults showed that, in addition to Y153 (Liu et al., 2006; Rush
et al., 2005; Figure S1A), Y106 of PSMA7 was also phosphory-
lated (Figure 1B). Further, proteasome-incorporated exogenous
PSMA7 was prepared by gel filtration (fraction no. 4–no. 6 withCproteasomal peptidase activity; Figures S1B and S1C) followed
by anti-FLAG immunoprecipitation; both Y106 and Y153 on
proteasome-incorporated PSMA7 were further confirmed by
LC-MS/MS (Figures 1C and S1D).
By phosphorylation-deficient mutation, it was further demon-
strated that the proteasome-incorporated or unincorporated
PSMA7 was similarly phosphorylated at Y106 by c-Abl kinase
(Figure 1D). Moreover, PSMA7(P126A), a c-Abl-association-
defective mutant due to mutation within the PXXP consensus
motif essential for c-Abl SH3 binding (Ren et al., 1993; Fig-
ure S1E), also demonstrated impaired phosphorylation (Fig-
ure 1D). The significantly decreased tyrosine phosphorylation
on PSMA7 with only Y106F mutation may be likely explained
by the fact that many tyrosine kinases, such as Src or epidermal
growth factor receptor, show synergistic effects with the activity
at multiple phosphorylate sites in a substrate.
c-Abl-Mediated Phosphorylation Regulates PSMA7
Expression
It was found that the ectopically expressed PSMA7, but not other
alpha subunits, was upregulated by c-Abl or Arg (Figure 2A).
Moreover, the proteasome-unincorporated exogenous PSMA7ell Reports 10, 484–496, February 3, 2015 ª2015 The Authors 485
Figure 2. c-Abl-Mediated Phosphorylation Regulates PSMA7 Expression
(A–C) The exogenously expressed PSMA7 levels in the whole (A) or fractionated (B and C) lysates of HEK293 cells transfected with the indicated plasmids were
detected by immunoblotting.
(D–F) The whole lysates of indicated cells were detected by immunoblotting. c-abl/arg/MEFs were rescued by the electrotransfection of c-Abl-expressing
plasmid (D). (c-Abl+Arg)RNAi no. 1 and no. 2 are two different c-Abl/Arg double-knockdown cell lines (E). K562 CML cells were treated with 10 mM STI571 or
DMSO for 18 hr (F). The qualification of three independent experiments was presented as the mean ± SD (*p < 0.05; **p < 0.005).(endogenous PSMA7 was hardly detected in unincorporated
fractions as shown by Figure S2A) level was clearly upregulated
by the coexpression of c-Abl or Arg, whereas the incorporated
PSMA7 level was not much affected (Figure 2B). In concert
with the findings, PSMA7 containing Y106F or P126A mutation
demonstrated a more significantly decreased expression level
than Y153F mutation did, in proteasome-unincorporated, but486 Cell Reports 10, 484–496, February 3, 2015 ª2015 The Authorsnot incorporated, fraction (Figure 2C). The observation that the
phosphorylation-deficient PSMA7 could be properly incorpo-
rated into proteasome suggested that the incorporation of
PSMA7 was not much regulated by its tyrosine phosphorylation
(Figure 2C).
Further, it was observed that, although PSMA7 level was
moderately decreased in the c-abl/ MEFs compared with
that in wild-type MEFs, it was remarkably decreased in
c-abl/arg/MEFs (Figure 2D), indicating the redundant func-
tion of c-Abl and Arg in PSMA7 regulation. PSMA7 expression
was significantly rescued by the reintroduction of c-Abl (Fig-
ure 2D), but not kinase-dead c-Abl(K290R) (Figure S2B). Obvious
PSMA7 downregulation was also observed in two independent
c-Abl/Arg double-knockdown MCF-7 cell lines generated by
RNAi (Figures 2E and S2C) or in c-Abl/Arg-specific inhibitor
STI571-treated K562CML cells that express constitutively active
Bcr-Abl (Figure 2F). Unlike PSMA5, little if any PSMA7was found
to be present as a free monomer in tested cells by gel filtration
(Figure S2A), which was in concert with the other reports (Jør-
gensen and Hendil, 1999). Therefore, the PSMA7 detected in
the above experiments (Figures 2D–2F) primarily arose from
PSMA7 in proteasome complexes. These results suggested
that, in physiological contexts, c-Abl may regulate the level of
proteasome-incorporated PSMA7 bymodulating PSMA7 supply
for proteasome assembly. However, c-Abl had little if any effect
on proteasome level when PSMA7was sufficiently supplied (Fig-
ures 2B and 2C, right panels).
c-Abl-Mediated Phosphorylation Inhibits the Ubiquitin-
Proteasomal Degradation of PSMA7
Little if any effect on PSMA7mRNA level was observed by c-abl/
arg deficiency (Figure S3A).We next investigated themechanism
other than transcription responsible for c-Abl/Arg-regulated free
PSMA7 level in detail using a N-terminal FLAG-tagged PSMA7
(FLAG-PSMA7), which was similarly regulated by c-Abl (Figures
S3B and S3C) and less presented as an incorporated form than
PSMA7-FLAG (3% versus 10%) due to the lower incorpora-
tion efficiency (Groll et al., 1997; Figure S3D). Therefore, the
interference of incorporated, long-living PSMA7 could be better
avoided (Figures 2C and 3C). The pulse-chase experiment by
[35S]-methionine labeling demonstrated that the half-life of
wild-type PSMA7 was extended from 20 hr to more than
60 hr by coexpression of c-Abl or Arg (Figure 3A). Comparing
with Y153F mutant (15 hr), the half-life of the mutant containing
Y106F or P126A was significantly decreased to6 hr and9 hr,
respectively. A similarly lowered stability was also observed
when wild-type or Y106F mutant PSMA7 was expressed in
c-abl/arg/ MEFs, indicating that PSMA7 stability was de-
pendent on Abl kinases, but not due to a structural problem
associated with the Y106F mutation (Figure 3B).
In concert with the findings that c-Abl regulates the expression
of free other than proteasome-incorporated PSMA7 (Figures 2B
and 2C), the stability of proteasome-unincorporated, but not
incorporated, PSMA7 was significantly regulated by Y106 phos-
phorylation in cycloheximide (CHX)-treated cells (Figure 3C).
Also, the proteasome complex stability was not much effected
by the incorporation of ectopically expressed wild-type or
Y106F PSMA7 (Figure 3C, lower panel), implying that Abl-medi-
ated PSMA7 phosphorylation may modulate proteasome level
by regulating PSMA7 supply for newborn proteasome, but not
the turnover of assembled proteasomes.
Next, we found that the lowered PSMA7 levels in c-
abl/arg/ MEFs can be partially rescued by proteasome in-
hibitor lactacystin, but not by lysosomal inhibitor concanamycin
A (Li et al., 2010; Figure 3D). The half-life of exogenous PSMA7Cwas also prolonged by lactacystin treatment (Figure 3E).
In vitro degradation assay also demonstrated that proteasome
inhibitor MG132 could suppress the degradation of both [35S]-
labeled wild-type and Y106F PSMA7 in the absence of c-Abl
(Figure 3F). Notably, the degradation of wild-type, but not
Y106F, PSMA7 was significantly blocked after the pretreatment
by recombinant c-Abl kinase. These results indicate that the
PSMA7 subunit is susceptible to proteasomal degradation in
the absence of the c-Abl kinase.
Further, a distinct polyubiquitination of exogenously ex-
pressed PSMA7 was observed after MG132 treatment, which
was decreased by more than 70% by the coexpression of
c-Abl, but not c-Abl(K290R) (Figure 3G, left panel). Consistent
with the significantly decreased stability, PSMA7(Y106F),
PSMA7(Y106/153F), or PSMA7(P126A) mutants each demon-
strated robust polyubiquitination compared with wild-type or
PSMA7(Y153F) (Figure 3G, right panel). Polyubiquitination was
substantially impaired upon the expression of conjugation-defi-
cient ubiquitin Ub(G76A) (Figure 3H).
Then, the anti-FLAG immunoprecipitates prepared from the
extracts of HEK293-expressing FLAG-PSMA7(Y106F) were
resolved by SDS-PAGE. Both PSMA7 and ubiquitin were found
to be present in the protein bands assayed ranging from 35 to
140 kDa by LC-MS/MS analysis (Figure S3E; Table S1). Quanti-
tative proteomics demonstrated the ubiquitin modification on
K115 of PSMA7 (Kim et al., 2011). Accordingly, compared with
the PSMA7(Y106F), PSMA7(Y106F/K115R) had significantly
impaired polyubiquitination (Figure 3I), as well as partially
rescued PSMA7 expression (Figure 3J). The polyubiquitination
of FLAG-PSMA7(Y106F) was also detected by anti-FLAG immu-
noblotting, excluding the false-positive polyubiquitination sig-
nals of PSMA7-associated polyubiquitinated proteins (Figure 3I,
right panel). These findings collectively support the hypothesis
that the c-Abl kinase regulates the ubiquitination and then the
proteasomal degradation of PSMA7.
The Ubiquitin-Protein Ligase BRCA1 Is Potentially
Responsible for PSMA7 Polyubiquitination
The ubiquitin ligase BRCA1 that is associated with c-Abl
kinase (Foray et al., 2002) was initially identified in
PSMA7(Y106F) immunoprecipitates by LC-MS/MS. Further
studies showed that BRCA1 was efficiently coimmunoprecipi-
tated with PSMA7(Y106F), but not with PSMA7(Y153F) or wild-
type PSMA7 unless in the presence of STI571 (Figure 4A). More-
over, full-length BRCA1 was found to directly associate with
PSMA7 expressed in E.coli as shown by far-western blot (Fig-
ure 4B). Notably, a proportion of PSMA7(Y106F) was found to
be coeluted with BRCA1 complexes in the first fraction with UV
absorbance by gel filtration (Sy et al., 2009; Figure 4C, upper
panel), and the association of BRCA1 with PSMA7(Y106F) in
fraction no. 1 was further confirmed (Figure 4C, lower panel).
These results indicate that the polyubiquitinated PSMA7 should
be proteasome unassociated, because active proteasome com-
plexes were eluted in fractions no. 4–no. 6 (Figures S1B and
S2A).
The knockdown of BRCA1 expression by RNAi resulted in
compromised ubiquitination (Figure 4D) and remarkably
increased expression of PSMA7(Y106F) (Figure S4A). Theell Reports 10, 484–496, February 3, 2015 ª2015 The Authors 487
Figure 3. c-Abl-Mediated Tyrosine Phosphorylation Inhibits PSMA7 Degradation through Ubiquitin-Proteasome Pathway
(A) The indicated proteins labeled with [35S]-methionine were chased for indicated time in HEK293 cells. Anti-FLAG immunoprecipitates were analyzed by SDS-
PAGE electrophoresis and autoradiography. The stability (% PSMA7 remaining) was indicated as the mean ± SD of three independent experiments.
(B) The level of exogenous PSMA7 in the whole lysates of c-abl/arg/MEFs treated with 100 mg/ml cycloheximide (CHX) was chased for indicated time and
analyzed by immunoblotting.
(legend continued on next page)
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polyubiquitination of PSMA7(Y106F) was not observed in
BRCA1-deficient HCC1937 breast carcinoma cells unless an
exogenously active BRCA1, but not the enzymatically inactive
BRCA1(I26A), was reintroduced into the cells (Figure 4E). Simi-
larly, significant polyubiquitination of PSMA7 was observed
only if BRCA1, but not BRCA1(I26A) mutant, was added into
in vitro ubiquitination system together with BARD1 (Figure 4F).
In vitro polyubiquitination of PSMA7 was suppressed with the
presence of recombinant c-Abl kinase (Figure 4G). These results
suggest that the BRCA1 is the (probably not the only) E3 ubiquitin
ligase of PSMA7 with Y106 phosphorylation deficiency. More-
over, little if any difference between the half-life, ubiquitination,
and BRCA interaction of FLAG-PSMA7 and PSMA7-FLAG was
observed (Figures S4B–S4D), excluding the possibility that the
ubiquitination and degradation of FLAG-PSMA7 were raised by
its lower incorporation efficiency.
Cellular Proteasome Abundance Is Controlled by
PSMA7 Stability
We next sought to determine whether the Abl-kinases-regulated
supply of PSMA7 was involved in the regulation of cellular pro-
teasome abundance. Exogenous expression of c-Abl or Arg,
but not the inactivemutant c-Abl(K290R) or Arg(K337R), resulted
in an increased cellular proteasome abundance (Figure 5A).
Moreover, comparing with wild-type cells, mature 20S protea-
some levels in c-abl/arg-deficient or knockdown cells were
decreased by 75% and 40%, respectively (Figure 5B). Cells
bearing similar PSMA7 and proteasome level achieved by
PSMA7 small interfering RNA (siRNA) retained a viability of
80%–95% (Figures 5B, S5A, and S5B). Notably, the reduced
20S proteasome level in c-abl/arg/MEFs could be rescued
by the exogenous introduction of c-Abl or PSMA7 (Figure 5B,
left), suggesting that PSMA7 is the major (if not the only) protea-
some subunit that is regulated by the Abl kinases. It was also
noted that the level of other 20S subunits (Figure 5C), but not
the constitutive 19S subunits (Figure S5C), was similarly downre-
gulated in the c-abl/arg/ MEFs, implying that the 20S sub-
units are either coordinately assembled into proteasomes or
are subjected to degradation rapidly.
Further, the treatment of both K562 cells and promyelocytic
leukemia HL60 cells (expressing c-Abl, but not Bcr-Abl) with
STI571 resulted in a dose-dependent reduction of mature pro-
teasome level and the proteasome reduction was more remark-
able in K562 cells than that in HL60 cells (Figure 5D). Moreover,
the 20S proteasome level in the hepatic tissue of STI571-admin-(C) FLAG-PSMA7 (1 mg)- or FLAG-PSMA7(Y106F) (5 mg)-transfected HEK293 cel
lysates were analyzed by immunoblotting. To analyze the 20S proteasome be
incorporated fraction were detected by immunoblotting with anti-20S proteasom
(D) PSMA7 level in c-abl/arg/MEFs treated with or without 10 mM lactacystin
3 was used as a control that was sensitive to ConA treatment.
(E) c-abl/arg/ MEFs electrotransfected with FLAG-PSMA7 were pretreated w
times. The lysates were analyzed by immunoblotting.
(F) [35S]-labeled FLAG-PSMA7 or FLAG-PSMA7 (Y106F) were preincubated with
were then added to the extracts of c-abl/arg/MEFs. The same cell extracts pr
of acid-soluble fraction was quantified by liquid scintillation counting. The results
(G–I) HEK293 cells transfected with the indicated plasmids were treated with 10
lysates of HEK293 cells were normalized by FLAG-PSMA7 level and then analyz
(J) Lysates of HEK293 cells expressing the indicated proteins were analyzed by
Cistratedmicewas alsomarkedly reduced by approximately 40%,
as compared with control mice (**p < 0.05; Figure 5E).
Dual Roles of c-Abl Kinases in Physiological
Proteasome-Dependent Proteolysis
Our previous study has demonstrated that the c-Abl-mediated
phosphorylation of PSMA7 resulted in an inhibited proteasomal
activity in vitro and in the cells (Liu et al., 2006). However, the
phosphorylation of PSMA7 also contributes to the maintenance
of proteasome abundance by protecting proteasome subunits
fromdegradation. In concert with these findings, despite the pro-
teasome level in c-abl/arg/MEFs was only less than 25% of
that in wild-type MEFs (the left of Figures 5B, 6A, and 6B), the
c-abl/arg/MEFs demonstrated only a mildly impaired over-
all proteasomal degradation capacity (achieved by the normali-
zation of cellular b-actin level) by in-gel peptidase analysis (the
middle of Figure 6A and the right of Figure 6B) or lysates pepti-
dase assay (Figure S6A) with Suc-Leu-Leu-Val-Tyr-7-amino-4-
methylcoumarin (LLVY-AMC) as small molecular substrates.
The contradiction between cellular proteasome level and overall
proteasomal degradation capacity was delineated by the obser-
vation that the proteasomal activity of a given number of protea-
somes (achieved by the normalization of cellular proteasome
level) in c-abl/arg/ MEFs was more than three times higher
than that of wild-type MEFs because of c-abl/arg deficiency
(the right of Figures 6A and 6B), which was consistent with the
finding of Abl-kinase-mediated proteasome inhibition.
To investigate the proteasomal degradation of ubiquitin-con-
jugated substrates in living cells, wild-type and c-abl/arg/
MEFs were transfected with a short-lived ubiquitin-dependent
proteolysis substrate, Ub-R-GFP, or a stable control, Ub-M-
GFP (Dantuma et al., 2000). Ub-R-GFP has a longer half-life in
the c-abl/arg-knockout cells than that in wild-type cells
(100 min versus 70 min), which indicated a somewhat decel-
erated degradation of ubiquitinylated proteins in c-abl/arg-defi-
cient cells (Figure 6C). It was also observed that more than
85% of the Ub-R-GFP could be degraded in both cell lines,
whereas accordingly more Ub-R-GFP accumulation (13.6%
versus 9.6% relative to Ub-M-GFP in the presence of MG132)
was observed in c-abl/arg/ MEFs (Figure 6D), suggesting
that the less-efficient degradation activity may be enough for
c-abl/arg-deficient cells to deal with most of physiologically pro-
duced ubiquitinated proteins and maintain the viability. Notably,
c-abl/arg/MEFs demonstrated a much-higher sensitivity to
proteasome inhibition because of the much-higher proteasomalls were treated with CHX for the indicated times and then the fractionated cell
aring exogenous PSMA7, anti-FLAG immunoprecipitates prepared from the
e antibody (the lowest panel).
or concanamycin A (ConA) for 12 hr was analyzed by immunoblotting. Galectin-
ith lactacystin or DMSO for 12 hr and then treated with CHX for the indicated
(open bar) or without (hatched bar) recombinant c-Abl kinase for 30 min and
etreated with 10 mMMG132 (black bar) were used as a control. The radioactivity
were expressed as the mean ± SD of three independent experiments.
mM MG132 for 10 hr. Anti-FLAG immunoprecipitates prepared from the whole
ed by immunoblotting.
immunoblotting.
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Figure 4. BRCA1 Is a Potential Ubiquitin
Ligase of PSMA7
(A) Anti-FLAG immunoprecipitates prepared from
the whole lysates of HEK293 cells cotransfected
with indicated plasmids were normalized by
FLAG-PSMA7 level and then analyzed by immu-
noblotting.
(B) Anti-HA immunoprecipitates prepared from
cells transfected with HA-BRCA1 or HA vector
were subjected to SDS-PAGE and blotted onto
nitrocellulose membrane. The nitrocellulose
membrane was incubated with soluble GST-
PSMA7 and then analyzed by anti-GST antibody.
(C) The whole lysates of HEK293 cells coex-
pressing HA-BRCA1, Myc-c-Abl, and PSMA7
(Y106F)-FLAG were subjected to gel filtration. The
indicated fractions (upper panel) and the anti-
FLAG immunoprecipitates prepared from fraction
no. 1 (lower panel) were analyzed by immuno-
blotting.
(D and E) Anti-FLAG immunoprecipitates or ly-
sates prepared from MG132-treated MCF-7/
scramble and MCF-7/BRCA1 siRNA cells (D) or
HCC1937 cells (E) transfected with indicated
plasmid were normalized by FLAG-PSMA7 level
and then analyzed by immunoblotting.
(F and G) The products of the in vitro ubiquitination
reactions were analyzed by immunoblotting with
indicated antibodies.activity of a given number of proteasomes but lower proteasome
abundance by c-abl/arg deficiency (Figure 6D). Accordingly,
more polyubiquitin-protein accumulation was observed by c-
abl/arg deficiency (Figures 7G and S6B), which became more
significant by MG132 treatment (the right of Figure S6B), sug-
gesting that the c-abl/arg-deficient MEFs could still efficiently
process the ubiquitinated proteins by partly impaired proteaso-
mal degradation capacity.
To further address the dynamic, dual role of c-Abl and Arg in
cellular proteasome-dependent proteolysis, proteasomal activ-490 Cell Reports 10, 484–496, February 3, 2015 ª2015 The Authorsity normalized to cell number was deter-
mined at different time points following
the reintroduction of exogenous c-Abl or
vector control into c-abl/arg/ MEFs.
Consistent with the above findings, the
PSMA7 and proteasome levels increased
significantly with the expression of c-Abl
(Figure 6E). Comparing with the control
transfected cells, the proteasomal activ-
ity (normalized by cellular proteasome
level) was sharply decreased because of
the phosphorylation-mediated inhibition
by gradually expressed exogenous c-
Abl kinase during the initial 10 hr and
was accompanied by a decreased overall
cellular proteasomal degradation capac-
ity (normalized by cellular b-actin level;
Figures 6E and 6F). However, prolonged
c-Abl expression resulted in a significant
increase in proteasome level from 10 hrto 30 hr accompanied with the gradual recovery of overall pro-
teasomal degradation capacity (Figures 6E and 6F).
The cytoplasmic c-Abl is activated by oxidative stress (Cao
et al., 2003; Sun et al., 2000). In accordance with PSMA7 phos-
phorylation, the levels of both the PSMA7 subunit and protea-
some complexes increased when MCF-7(Scramble), but not
the c-Abl/Arg knockdown MCF-7(KD), cells were exposed to
H2O2 (Figures 7A and 7B). The increased transcription of
PSMA7 gene was not observed under toxic oxidative conditions
(e.g., 0.52 mM H2O2) that activated Abl kinase (Ding et al.,
Figure 5. Proteasome Level Is Regulated by
c-Abl Tyrosine Kinase
(A–D) Extracts of the indicated cells were sub-
jected to native gel electrophoresis for protea-
some complex resolution (A, B, and D) or SDS-
PAGE (C) and then analyzed by immunoblotting.
The qualification of three independent experi-
ments was presented as the mean ± SD (D). NT,
no treatment.
(E) Proteasome levels in hepatic cells of mice
administrated with STI571 (50 mg/kg) or saline for
2 weeks were determined by immunoblotting. The
difference in the relative proteasome level be-
tween the two groups was statistically significant
(**p < 0.05).2003; Pickering et al., 2012; Figure S7A). Similar with c-Abl/Arg
knockout (Figures 6A and 6B), c-Abl/Arg knockdown resulted
in a notable decrease in proteasome level (Figures 5B and 7C;
0 mM H2O2) but only a slight decrease in overall proteasomal
degradation capacity (normalized by b-actin level; Figures 7C;
0 mM H2O2). The overall proteasomal degradation capacity of
MCF-7(KD) cells was significantly impaired with increased
H2O2 concentration, which was potentially due to ROS-induced
inactivation of the proteasome (Aiken et al., 2011; Grune et al.,
2011; Reinheckel et al., 1998). However, H2O2-induced impair-
ment of overall proteasomal degradation capacity was not
observed in MCF-7(Scr) cells (Figure 7C). As shown in Figure 7D,
although the proteasomal activity (normalized by cellular pro-
teasome level) in MCF-7(Scr) cells decreased according to
MCF-7(KD) cells under ROS stimulus, H2O2-induced increase
of proteasome abundance in the MCF-7(Scr) cells, but not in
MCF-7(KD) cells (Figure 7C), compensated for the loss of protea-
somal activity due to ROS damages. A similar result was also ob-Cell Reports 10, 484–496tained when cells were treated with
menadione, a ROS-inducing agent via
redox cycling that was used as a source
of vitamin K (Figures 7E and 7F). Further,
comparing with wild-type cells, the poly-
ubiquitin proteins accumulation in c-Abl/
Arg knockout or knockdown cells
became more accentuate when cells
were exposed to ROS (Figures 7G and
S7B). These results collectively support
the conclusion that proteasome abun-
dance and consequently overall protea-
somal degradation capacity of the cell
are dynamically regulated by c-Abl kinase
activity in response to stress stimuli.
DISCUSSION
The biogenesis and proteolytic activity of
26S/30S proteasome have been compre-
hensively studied by the findings of func-
tional proteasome regulator (Lee et al.,
2010; Lehmann et al., 2010; Vilchez
et al., 2012). However, the turnover ofproteasome subunits is seldom discussed. With few exceptions,
the biological significance of extensively reported proteasome
phosphorylation events has been largely unknown (Kikuchi
et al., 2010; Lu et al., 2008). In the present study, we have shown
that PSMA7 is phosphorylated at Y106 in addition to Y153 by c-
Abl kinase. Phosphorylation at both sites probably contributed to
the c-Abl-mediated proteasome inhibition, whereas Y106 is the
major site regulating the ubiquitin-proteasomal degradation of
proteasome-unincorporated PSMA7. According to crystal struc-
ture, neither Y153 nor Y106 of PSMA7 is located on the outer sur-
face of proteasome (Huber et al., 2012). Therefore, PSMA7
would be less phosphorylated at these sites when incorporated
into the proteasome. Moreover, it should not be excluded that
there are other potential phosphosites on PSMA7 or other pro-
teasome subunits, because c-Abl could directly phosphorylate
26S proteasome in vitro (Liu et al., 2006). In eukaryotes, the
absence of any 20S proteasome subunit, with the exception of
pre9/a3 in S. cerevisiae (Velichutina et al., 2004), results in a, February 3, 2015 ª2015 The Authors 491
Figure 6. Dual Roles of the c-Abl Kinase in
Proteasome-Dependent Proteolysis
(A and B) Extracts of the wild-type or abl/arg/
MEFswere subjected to native gel electrophoresis
for proteasome complex resolution or SDS-PAGE
and then analyzed by immunoblotting (A, left) or in-
gel proteasomal peptidase activity analysis using
LLVY-AMC fluorescence substrates (A, middle
and right). The extracts were normalized by
cellular b-actin or proteasome level as indicated.
The qualification of proteasome level and activity
were expressed as the mean ± SD of three inde-
pendent measures (B).
(C) After CHX treatment, the fluorescence intensity
of indicated cells expressing UB-R-GPF treated
with or without 10 mM MG132 was chased by PE
EnVision Spectrometer (Ex/Em: 485/535 nm) at
indicated time points. The results were expressed
as the mean ± SD of three independent measures.
(D) With (hatched bar) or without (open bar) 10 mM
MG132 treatment, the fluorescence intensity of
indicated cells transfected with UB-R-GPF or Ub-
M-GFP was assayed as in (C). RFU, relative fluo-
rescence units.
(E and F) c-abl/arg/ MEFs were electro-
transfected (70% efficiency) with a c-Abl-ex-
pressing plasmid or a control vector for indicated
times. Extracts of transfected cells were subjected
to immunoblotting after resolution by native gel or
SDS-PAGE electrophoresis (E) and proteasomal
activity assay using LLVY-AMC fluorescence
substrate (F). The proteasome levels were as-
sessed by densitometry of the western blot.
Relative overall proteasomal degradation capacity
(peptidase activity normalized by b-actin level;
solid-line with ,), relative proteasomal activity
(peptidase activity normalized by cellular protea-
some level; solid-line with B), and relative 20S
proteasome abundance (dashed line with,) of c-
Abl-rescued c-abl/arg/ MEFs over control
transfection were shown for each time point. The
values at 0 hr were defined as 1. The results were
expressed as the accessible mean ± SD of three
independent experiments.failure in 20S proteasome assembly and cell lethality (Wo´jcik and
DeMartino, 2002). We also observed a downregulation of all 20S
subunits, impaired proteasomal activity, and moderately ef-
fected viability by PSMA7 knockdown (Figures S5A and S5B),
which is accordant with the finding that PSMA7 supply shortage
caused by c-Abl/Arg knockout or inhibition impairs the protea-
some assembly (Figure 5).
It is also intriguing that the c-Abl kinase plays dual roles in
proteasome-dependent proteolysis. The depletion of c-abl/arg
results in a significantly decreased proteasome level but an
increased proteasomal activity (normalized by cellular protea-
some level), which may contribute to the modest decrease of492 Cell Reports 10, 484–496, February 3, 2015 ª2015 The Authorsoverall proteasomal degradation capacity
(normalized by cellular b-actin level) of c-
abl/arg-deficient cells (Figures 6A–6D).
Although the less-efficient degradation
activity is adequate for the survival of c-abl/arg-deficient cells, it may not be sufficient to dispose
massively produced ubiquitin conjugates under cellular stresses
such as heat shock, oxidative stress, starvation, or proteasome
inhibition (Seifert et al., 2010; Figures 7G and S7B). According
to the time-course-dependent effect of c-Abl on proteasome
(Figures 6E and 6F), ROS-activated c-Abl kinase may rapidly
phosphorylate and inhibit proteasome at the very early stage of
oxidative stress, protecting some short-living proteins, such as
p53 or p21, from proteasomal degradation and inducing cell-cy-
cle arrest for self-restoration. At meantime, the cellular protea-
some abundance is gradually increased along with Abl kinase
keeping activation, contributing to the removal of accumulated
oxidatively damaged proteins and avoiding potentially toxic ef-
fects. Lowered efficiency and dynamic regulation of proteasome
in c-abl/arg-null cells may contribute to the heightened sensitivity
to ROS-induced cell apoptosis (Cao et al., 2003). c-Abl-mediated
dynamic regulation of cellular proteasomal degradation activity is
likely to be a significant modulator by fine-tuning protein turnover
in response to stress or other environmental factors and provides
insight into the mechanism of c-Abl-involved tumorigenesis and
neurodegenerative diseases.
Proteasomal system is an important therapeutic target in ma-
lignant diseases treatment. Recent findings have demonstrated
that knockdown of any of the 20S core subunits sensitized the
cell to proteasomal inhibitor bortezomib and exhibited a synergis-
tic lethal phenotype (Chen et al., 2010). Similarly, enhanced cell
killingwas observed after treatment with the proteasome inhibitor
YU101 combined with knockdown of the transcription factor Nrf1
(Radhakrishnan et al., 2010). Our findings also demonstrated that
the proteasomal activity in c-abl/arg/ MEFs with lowered
proteasome abundance was more suppressed by MG132
compared to wild-type MEFs (Figure 6D), indicating that the pro-
teasome inhibitor sensitivity may be increased by c-Abl kinase in-
hibition. Myeloid leukemia cells constitutively expressing Bcr-Abl
have higher proteasome levels compared to normal peripheral
blood cells (Kumatori et al., 1990; Magill et al., 2004). Recent
studies have demonstrated that a greater than 85% decrease
inK562CMLcell proliferation by combinationSTI571/bortezomib
treatment has been observed compared to50%by bortezomib
alone or10%by STI571 alone at the same concentration (Yusuf
et al., 2009). Leukemic cells ormicewithCML treatedwith STI571
or dasatinib (a second-generation Abl kinase inhibitor) combined
with bortezomib exhibited suppressed tumor growth and signifi-
cantly prolonged life spans, offering a potential therapeutic op-
tion for CML (Heaney et al., 2010; Hu et al., 2009). These studies
strongly indicate that Abl kinase antagonists could be particularly
efficacious in combination anticancer therapies with proteasome
inhibitors based on their effects on Abl signaling, PSMA7, and
proteasome regulation.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
The HEK293 cells, MCF-7 cells, and MEFs derived from wild-type, c-abl/, or
c-abl/arg/ littermates (kindly provided by Dr. Anthony J. Koleske) were
grown in DMEM (GIBCO) supplemented with 10% heat-inactivated fetal
bovine serum (Hyclone), 2 mM L-glutamine, 100 units/ml penicillin, and
100 mg/ml streptomycin. K562 and HL60 cells were grown in RPMI 1640 me-
dium (GIBCO). Cells were treated with STI571 (Novartis), MG132 (BIOMOL),
lactacystin (BIOMOL), or concanamycin A (Sigma) as noted in the text. Cells
were transfectedwith Lipofectamine 2000 or the Neon electrotransfection sys-
tem (Invitrogen).
DNA Constructs
FLAG-tagged and hemagglutinin (HA)-tagged protein gene was cloned into
the pcDNA3 vector (Invitrogen). Myc-tagged protein gene was cloned into
the pCMV-Myc vector (Clontech). siRNAs (Table S2) were constructed into
the si-STRIKE U6 Hairpin Cloning System (Promega).
Immunoprecipitation and Immunoblotting Analysis
Cell lysates were prepared in lysis buffer containing 1% Nonidet P-40 (Cao
et al., 2003). Soluble proteins were subjected to immunoprecipitation with
anti-FLAG (M2; Sigma F2426), anti-PSMA7 (BIOMOL PW9140 or PW8120) an-Ctibodies, or mouse immunoglobulin G (IgG) (Sigma A0910). An aliquot of the to-
tal lysate (5%; v/v) was included as a control. The immunoblotting analysis was
performed with anti-PTyr (4G10; Millipore 16-105), anti-c-Abl (Santa Cruz
SC-131), anti-Myc (Santa Cruz SC-40), anti-FLAG horseradish peroxidase
(Sigma A8592), anti-b-actin (Santa Cruz SC-1616), anti-ubiquitin (Santa Cruz
SC-8017), anti-HA (Sigma H9658), anti-BRCA1 (Santa Cruz SC-6954), or
anti-20S proteasome (BIOMOL PW8195) antibodies. The antigen-antibody
complexes were visualized by enhanced chemiluminescence (ECL) (GE
Healthcare). Densitometry of the bands was analyzed by ImageJ (NIH).
Average of three independent experiments with SDs (error bars) and p values
as determined by t test were indicated.LC-MS/MS Analysis
FLAG-tagged PSMA7 immunoprecipitates prepared fromwhole-cell lysates or
gel-filtrated fractions were resolved by SDS-PAGE, and protein bands were
excised. After adequate trypsinization, phosphopeptides were enriched with
TiO2 resin (Calbiochem). LC-electrospray ionization-MS/MS-resolved pep-
tides were analyzed using a Q-TOF2 system (Micromass), and the data were
compared against SWISSPROT using the Mascot search engine (http://
www.matrixscience.com) for phosphorylation.Gel Filtration Chromatography
Cells were lysed by one pass through a French press in lysis buffer containing
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mMMgCl2, 10% glycerol (v/v), 1 mM
DTT, and 2 mM ATP. After cleared by centrifugation, cell lysates were loaded
on the Superdex200 gel column (HR30; GE Healthcare) and eluted with elution
buffer containing 25 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10% glycerol (v/v),
5mMMgCl2, and2mMATP. Eluateswere continuously collectedbyFC900 frac-
tion collector with 1.5 ml in each fraction when 0.01 absorbance units UV absor-
bance was monitored. The first fraction with UV absorbance was designated as
fractionno. 1.Fractionsno. 4–no. 6withpeptidaseactivitywerecombinedaspro-
teasome-incorporated subunit fraction, and fractions no. 12–no. 14 were com-
bined as proteasome-unincorporated subunit fraction (Figures S1B and S2A).Pulse-Chase Assay
Eighteen hours after the transfection of HEK293 cells with FLAG-tagged wild-
type or mutant PSMA7, cells were pulsed with [35S]-methionine (NEG 709A;
PerkinElmer Life and Analytical Sciences) for 1 hr inmethionine-free DMEM (In-
vitrogen) at a concentration of 10 mCi/ml. The cells were then washed, cultured
in complete DMEM supplemented with 5 mM cold methionine, and harvested
at the indicated times. Anti-FLAG immunoprecipitates were subjected to SDS-
PAGE and autoradiography.In Vitro Degradation Assay
[35S]-labeled PSMA7 proteins prepared by TNT Quick Coupled Transcription/
Translation Systems (Promega) were purified by anti-FLAG antibody affinity
chromatography. The purified proteins were preincubated with or without re-
combinant c-Abl kinase (Upstate Biotechnology) in kinase buffer at 37C for
60min and were then added to the extracts of c-abl/arg/MEFs pretreated
with or without the proteasome inhibitor MG132. Then, 13% trichloroacetic
acid was used to sediment the undegradated [35S]-labeled PSMA7 proteins
and the supernatant was subjected to liquid scintillation counting for quantita-
tion. The average counts per minute values obtained from three independent
experiments were presented.In Vitro Ubiquitination
To reconstitute the ubiquitination system in vitro, HA-BRCA1, HA-BARD, and
the indicated mutants were purified from HEK293 cells using affinity chroma-
tography with an anti-HA antibody and eluted with 10 mg/ml HA peptide
(Sigma). Similarly purified FLAG-PSMA7 was incubated with either HA-
BRCA1 or the I26A mutant together with or without HA-BARD at 37C for
90 min in a buffer containing E1, UbcH5c, biotinylated ubiquitin, and ATP
(Sigma). The reaction products were resolved by SDS-PAGE and were de-
tected by immunoblotting.ell Reports 10, 484–496, February 3, 2015 ª2015 The Authors 493
Figure 7. The Regulation of Proteasomal Activity by c-Abl Kinase in Response to ROS Stimuli
(A and B) MCF-7(Scr) or MCF-7(KD) cells were treated with 0.5 mM H2O2 for 0–4 hr (A) or with 0–2.0 mM H2O2 for 2 hr (B). Lysates or anti-PSMA7 immuno-
precipitates prepared from H2O2-treated cells were subjected to immunoblotting after resolution by native gel or SDS-PAGE electrophoresis.
(C and D) Cell extracts described in (B) were subjected to proteasomal activity assay using LLVY-AMC fluorescence substrate. Relative overall pro-
teasomal degradation capacity (peptidase activity normalized by b-actin level; solid-line) and relative proteasome abundance (dashed line) of indi-
cated cells at different treatment concentrations were shown in (C). The relative proteasomal activity of indicated cells (peptidase activity normalized by
cellular proteasome level; solid line) and the proteasomal activity ratio of MCF-7(Scr) and MCF-7(KD) (dashed line) at different concentrations were shown
in (D). The values at 0 mM H2O2 treatment were defined as 1. The results in (C) were expressed as the accessible mean ± SD of three independent
experiments.
(legend continued on next page)
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Proteasome Peptidase Activity Assay
Cell extracts were incubated in peptidase reaction buffer containing 0.1 mM
AMC-conjugated peptide substrates (Succinyl-LLVY-AMC; BIOMOL),
20 mM Tris-HCl (pH 7.4), 0.5 mM EDTA, 5 mM MgCl2, 1 mM DTT, 2 mM
ATP, and 0.02% SDS for 30 min at 37C. Fluorescence was assayed by fluo-
rescence spectrometer (Ex/Em: 380/460 nm; Fluoroskan Ascent FL; Thermo
Scientific). The relative fluorescence intensity was calculated from the mean
± SD of three independent experiments.
Native-PAGE Resolution of Proteasome Complexes
Cells were lysed by one pass through a French press in lysis buffer as
described above. The 23 native loading buffer contains 250 mM Tris-HCl
(pH 7.5), 50% glycerol (v/v), and 0.007% xylene cyanol (w/v). After resolved
by NuPAGE 3%–8% Tris-Acetate Gel (Invitrogen), the proteins from the native
gel were transferred to polyvinylidene fluoride membrane for immunoblotting
detection. The commercially purified 26S (PW9310; BIOMOL) and 20S
(PW8720; BIOMOL) proteasomes were used as a size marker for the native
gel (Figure S1B, left).
For in-gel proteasomal activity assay, incubate the native gel in proteasome
peptidase reaction buffer containing Succinyl-LLVY-AMC as described above
for 20 min at 37C. For stimulation of the 20S peptidase activity, add 0.02%
SDS. Then, visualize the gel on a UV transilluminator with a wavelength of
365 nm.
The Proteasomal Activity Assay in Living Cells
The detail of proteasomal activity assay in living cells has been described pre-
viously (Dantuma et al., 2000). The wild-type or c-abl/arg/ MEFs were
transfected with UB-R-GFP- or UB-M-GFP-expressing plasmid for 24 hr. After
treated with or without 10 mM MG132 for 10 hr, the cells were detached from
the culture dish by trypsin digesting, washed, and resuspended by 13 PBS
buffer and transferred into 96-well plate. The fluorescence intensity of each
well was assayed by PE EnVision Spectrometer (Ex/Em: 485/535 nm). The
relative fluorescence intensity was calculated from the mean ± SD of three in-
dependent experiments.
Animal Experiment
The BALB/c mice were orally administrated with 50 mg/kg of STI571 or saline
for 2 weeks. The proteasome levels in hepatic tissue of mice were analyzed by
immunoblotting. Animal studies were approved by Institutional Ethics
Committee.
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